一分钟看懂
这是一项关于结直肠癌的III 期研究，登记的药物或干预包括Second-Line Chemotherapy；Radiation Therapy；Cadonilimab (AK104)，当前状态为尚未开始招募。登记地点显示中国上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Second-Line Chemotherapy；Radiation Therapy；Cadonilimab (AK104) · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Fudan University Shanghai Cancer Center · 上海
公开的入选条件
- 1. Histopathologically confirmed colorectal adenocarcinoma.
- 2. Tumors confirmed pMMR by immunohistochemistry or MSI-L/MSS via gene sequencing.
- 3. Metastases limited to peritoneum only, no metastases in other organs.
- 4. No moderate or massive ascites; only trivial physiological effusion without drainage requirement.
- 5. No symptomatic intestinal obstruction and no obstructive signs on imaging; patients can take food normally.
- 6. Baseline CT/MRI confirms peritoneal metastases.
- 7. Positive baseline FAPI PET/CT: at least one peritoneal mass lesion with long diameter ≥1 cm and markedly elevated SUVmax suitable for radiotherapy contouring.
- 8. At least one measurable lesion per RECIST v1.1 criteria.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07815834；登记信息更新于 2026-09-11。